Transcriptome Alteration in the Diabetic Heart by Rosiglitazone: Implications for Cardiovascular Mortality

The type 2 diabetes medication, rosiglitazone, has come under scrutiny for possibly increasing the risk of cardiac disease and death. To investigate the effects of rosiglitazone on the diabetic heart, we performed cardiac transcriptional profiling of a murine model of type 2 diabetes, the C57BL/KLS-leprdb/leprdb (db/db) mouse. We compared cardiac gene expression profiles from three groups: untreated db/db mice (db-c), db/db mice after rosiglitazone treatment (db-t), and non-diabetic db/+ mice. Mice were divided into three groups: Non-diabetic controls (db/+), untreated diabetic controls (db-c), and rosiglitazone-treated diabetic mice (db-t). Whole-heart RNA from five mice from each of the three groups after four months with or without treatment was used for microarray analysis.Universal Reference RNAs for mouse (Stratagene, La Jolla, CA) were purchased as microarray reference controls.2型糖尿病治疗药物罗格列酮（rosiglitazone）因可能增加心血管疾病与死亡风险而受到广泛关注。为探究罗格列酮对糖尿病心脏的影响，本研究针对2型糖尿病小鼠模型——C57BL/KLS-leprdb/leprdb（db/db）小鼠开展心脏转录谱分析。本研究将对三组样本的心脏基因表达谱进行对比：未接受治疗的db/db小鼠（db-c）、经罗格列酮治疗的db/db小鼠（db-t）以及非糖尿病db/+小鼠。实验小鼠被分为三组：非糖尿病对照组（db/+）、未治疗糖尿病对照组（db-c）以及经罗格列酮治疗的糖尿病小鼠（db-t）。在经过四个月的给药或对照处理后，采集三组小鼠各5只的全心脏RNA样本，用于微阵列（microarray）分析。本研究使用的小鼠通用参考RNA购自Stratagene公司（美国加利福尼亚州拉霍亚市），作为微阵列分析的对照样本。